Altamira Therapeutics (NASDAQ:CYTO) expanded its existing marketing and distribution agreement with Wellesta Holding of Singapore for Altamira’s Bentrio nasal spray for personal protection against airborne viruses and allergens.
In addition to India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam, Wellesta will now also promote and sell Bentrio in the Philippines and Morocco after it is registered with the regulatory agencies in those two countries.
“The Philippines and Morocco, with populations of approximately 110 million and 37 million, respectively, represent two attractive new markets for Bentrio,” Thomas Meyer, founder, chairman and CEO of Altamira, said in a statement.
“Wellesta has proven to be a strong commercialization partner for us, and we look forward to continuing to work with its well experienced team,” he added.
Having already obtained marketing clearances for Bentrio in Malaysia and Singapore, Wellesta is now making preparations and procedures for registration in the other six countries covered by the agreement.
